Effect of pravastatin on functional recovery from sciatic nerve crush injury in rats

doi:10.12307/2025.248

Abstract

Abstract: BACKGROUND: Pravastatin is a clinically effective drug for the treatment of hypercholesterolemia and is now found to play a beneficial role in the treatment of CNS injury; however, the mechanism remains unknown.
OBJECTIVE: To ascertain the possible mechanism of action and whether pravastatin medication can expedite functional recovery following sciatic nerve crush injury.
METHODS: Male Sprague-Dawley rats were randomly assigned into: pravastatin (sciatic nerve crush injury+pravastatin gavage), negative control (sciatic nerve crush injury+saline gavage), and sham operation (sciatic nerve exposure but no injury+saline gavage). While the other two groups received comparable amounts of saline gavage, the pravastatin group received postoperative pravastatin (5 mg/kg) by gavage for 1 week. The general conditions of the rats in each group were observed after operation. Sciatic function index was evaluated at the end of the 2nd, 4th, 6th, and 8th week after operation, and the wet mass ratio of the gastrocnemius muscle was measured at the end of the 8th week after operation. The levels of inflammatory cytokines in serum were measured using ELISA. Histomorphometrics was used to measure the number of myelinated nerve fibers, fiber diameter, axon diameter, and myelin sheath thickness. RT-qPCR assay was used to measure the relative mRNA expression of nerve growth factor and brain-derived neurotrophic factor, and western blot was used to measure the protein expression of growth-associated protein 43.
RESULTS AND CONCLUSION: Compared with the negative control group, the sciatic function index in the pravastatin group recovered faster (P < 0.05) and was closer to the level of the sham operation group, the expression of tumor necrosis factor α and interleukin 6 in serum was lower (P < 0.05) and close to that of the sham operation group, and the relative mRNA expression of nerve growth factor and brain-derived neurotrophic factor in the sciatic nerve increased (P <
0.05 or P < 0.01), the relative protein expression of growth-associated protein 43 in the sciatic nerve was also significantly increased (P < 0.05), the number of myelinated nerve fibers was increased more, and the values of fiber diameter, axon diameter, and myelin sheath thickness were larger (P < 0.01) and closer to those of the sham operation group. To conclude, treatment with pravastatin accelerates functional recovery from sciatic nerve crush injury by a possible mechanism of inhibiting the expression of tumor necrosis factor α and interleukin 6 and promoting the secretion of neurotrophic factors nerve growth factor and brain-derived neurotrophic factor.

Key words: peripheral nerve injury, pravastatin, functional recovery, neurotrophic factor, sciatic function index

CLC Number:

Liu Zan, An Ran, Li Baocheng. Effect of pravastatin on functional recovery from sciatic nerve crush injury in rats [J]. Chinese Journal of Tissue Engineering Research, 2025, 29(5): 942-950.

Figures/Tables 7

References

[1] KAPLAN B, LEVENBERG S. The Role of Biomaterials in Peripheral Nerve and Spinal Cord Injury: A Review. Int J Mol Sci. 2022;23(3):1244.
[2] LOPES B, SOUSA P, ALVITES R,et al. Peripheral Nerve Injury Treatments and Advances: One Health Perspective. Int J Mol Sci. 2022;23(2):918.
[3] ZHANG M, LI L, AN H, et al. Repair of Peripheral Nerve Injury Using Hydrogels Based on Self-Assembled Peptides. Gels. 2021;7(4):152.
[4] PFISTER BJ, GORDON T, LOVERDE JR,et al. Biomedical engineering strategies for peripheral nerve repair: surgical applications, state of the art, and future challenges. Crit Rev Biomed Eng. 2011;39(2):81-124.
[5] SLAVIN BR, SARHANE KA, VON GUIONNEAU N, et al. Insulin-Like Growth Factor-1: A Promising Therapeutic Target for Peripheral Nerve Injury. Front Bioeng Biotechnol. 2021;9:695850.
[6] FERDOWSI S, ABDOLMALEKI A, ASADI A,et al. Effect of Azithromycin on Sciatic Nerve Injury in the Wistar Rats. Neurochem Res. 2023;48(1): 161-171.
[7] DIVAC N, AKSIĆ M, RASULIĆ L, et al. Pharmacology of repair after peripheral nerve injury. Int J Clin Pharmacol Ther. 2021;59(6):447-462.
[8] HUANG W, YI S, ZHAO L. Genetic Features of Young and Aged Animals After Peripheral Nerve Injury: Implications for Diminished Regeneration Capacity. Cell Mol Neurobiol. 2023;43(8):4363-4375.
[9] SIDHU G, SAPRA A. Pravastatin. 2023 Jun 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
[10] SOLHEIM S, SELJEFLOT I, ARNESEN H, et al. Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis. 2001;157(2):411-415.
[11] SOMMEIJER DW, MACGILLAVRY MR, MEIJERS JC,et al. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care. 2004;27(2):468-473.
[12] LU P, LIU J, PANG X. Pravastatin inhibits fibrinogen- and FDP-induced inflammatory response via reducing the production of IL-6, TNF-α and iNOS in vascular smooth muscle cells. Mol Med Rep. 2015;12(4):6145-6151.
[13] SATO F, WAJIMA D, TAKESHIMA Y, et al. Neuroprotective effects of pravastatin in cerebral venous infarction in a rat model. IBRO Neurosci Rep. 2023;14:202-209.
[14] MAZARD T, RITZENTHALER T, DAILLER F. Pravastatin may improve neurological outcome following low-grade aneurysmal subarachnoid hemorrhage. J Clin Neurosci. 2022;98:11-14.
[15] BERGER C, XIA F, MAURER MH, et al. Neuroprotection by pravastatin in acute ischemic stroke in rats. Brain Res Rev. 2008;58(1):48-56.
[16] YALÇıNKAYA B, OCAK H, ÇOLAK AF, et al. Sciatic neurotmesis and periostitis ossificans progressiva due to a traumatic/unexpected glass injury: a case report. J Yeungnam Med Sci. 2024;41(1):45-47.
[17] HUSSAIN G, WANG J, RASUL A,et al. Current Status of Therapeutic Approaches against Peripheral Nerve Injuries: A Detailed Story from Injury to Recovery. Int J Biol Sci. 2020;16(1):116-134.
[18] VIJAYAVENKATARAMAN S. Nerve guide conduits for peripheral nerve injury repair: A review on design, materials and fabrication methods. Acta Biomater. 2020;106:54-69.
[19] LIU X, DUAN X. Mechanisms and Treatments of Peripheral Nerve Injury. Ann Plast Surg. 2023;91(2):313-318.
[20] ZIMMERMANN KS, AMAN M, HARHAUS L, et al. Improving outcomes in traumatic peripheral nerve injuries to the upper extremity. Eur J Orthop Surg Traumatol. 2023 Oct 21. doi: 10.1007/s00590-023-03751-3.
[21] SAFA B, JAIN S, DESAI MJ, et al. Peripheral nerve repair throughout the body with processed nerve allografts: Results from a large multicenter study. Microsurgery. 2020;40(5):527-537.
[22] PEREIRA C, LAZAR SV, WANG A. Bioengineering approaches for nerve graft revascularization: Current concepts and future directions. WIREs Mech Dis. 2023;15(4):e1609.
[23] YU T, AO Q, AO T, et al. Preparation and assessment of an optimized multichannel acellular nerve allograft for peripheral nerve regeneration. Bioeng Transl Med. 2022;8(4):e10435.
[24] LOVATI AB, D’ARRIGO D, ODELLA S,et al. Nerve Repair Using Decellularized Nerve Grafts in Rat Models. A Review of the Literature. Front Cell Neurosci. 2018;12:427.
[25] BOLANDGHAMAT S, BEHNAM-RASSOULI M. Recent Findings on the Effects of Pharmacological Agents on the Nerve Regeneration after Peripheral Nerve Injury. Curr Neuropharmacol. 2020;18(11):1154-1163.
[26] DAIMON M, AOMI S, KAWAMATA T,et al. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces delayed neuronal death following transient forebrain ischemia in the adult rat hippocampus. Neurosci Lett. 2004;362(2):122-126.
[27] TRAMONTINA AC, WARTCHOW KM, RODRIGUES L,et al. The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer’s disease in rats. J Neural Transm (Vienna). 2011;118(11):1641-1649.
[28] AL-SAEDI HF, PANAHI Y, GHANIMI HA,et al. Enhancement of nerve regeneration with nimodipine treatment after sciatic nerve injury. Fundam Clin Pharmacol. 2023;37(1):107-115.
[29] SHAN C, ZHANG C, ZHANG C. The Role of IL-6 in Neurodegenerative Disorders. Neurochem Res. 2024 Jan 16. doi: 10.1007/s11064-023-04085-6.
[30] KOULAXOUZIDIS G, REIM G, FLUHR JW,et al. In Situ Deactivation of Interleukin-6 Enhances Early Peripheral Nerve Regeneration in a Murine Injury Model. J Reconstr Microsurg. 2015;31(7):508-515.
[31] HUANG Z, ZHONG L, ZHU J,et al. Inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy. Ann Transl Med. 2020;8(24):1681.
[32] IDRISS HT, NAISMITH JH.TNF alpha and the TNF receptor superfamily: structure-function relationship(s). MicroscResTech. 2000;50(3):184-195.
[33] URABE H, TERASHIMA T, LIN F, et al. Bone marrow-derived TNF-α causes diabetic neuropathy in mice. Diabetologia. 2015;58(2):402-410.
[34] LORENZINI L, BALDASSARRO VA, STANZANI A,et al. Nerve Growth Factor: The First Molecule of the Neurotrophin Family. Adv Exp Med Biol. 2021;1331:3-10.
[35] KOPACH O, PAVLOV AM, SINDEEVA OA, et al. Biodegradable Microcapsules Loaded with Nerve Growth Factor Enable Neurite Guidance and Synapse Formation. Pharmaceutics. 2020;13(1):25.
[36] MIZUSHIMA N, KOMATSU M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728-741.
[37] DODSON M, WANI WY, REDMANN M, et al. Regulation of autophagy, mitochondrial dynamics, and cellular bioenergetics by 4-hydroxynonenal in primary neurons. Autophagy. 2017;13(11): 1828-1840.
[38] LI R, LI D, WU C, et al. Nerve growth factor activates autophagy in Schwann cells to enhance myelin debris clearance and to expedite nerve regeneration. Theranostics. 2020;10(4):1649-1677.
[39] FLETCHER JL, MURRAY SS, XIAO J. Brain-Derived Neurotrophic Factor in Central Nervous System Myelination: A New Mechanism to Promote Myelin Plasticity and Repair. Int J Mol Sci. 2018;19(12):4131.
[40] ARANAZ I, ACOSTA N, REVUELTA J, et al. Fast and Sustained Axonal Growth by BDNF Released from Chitosan Microspheres. Mar Drugs. 2023;21(2):91.
[41] LAN G, DU J, CHEN X,et al. Association of APOE-ε4 and GAP-43-related presynaptic loss with β-amyloid, tau, neurodegeneration, and cognitive decline. Neurobiol Aging. 2023;132:209-219.
[42] SHI LF, WANG CJ, YU KW, et al. An Enriched Environment Promotes Motor Function through Neuroprotection after Cerebral Ischemia. Biomed Res Int. 2023;2023:4143633.
[43] CHATO-ASTRAIN J, RODA O, SÁNCHEZ-PORRAS D, et al. Peripheral nerve regeneration through nerve conduits evokes differential expression of growth-associated protein-43 in the spinal cord. Neural Regen Res. 2023;18(8):1852-1856.
[44] MANKAVI F, IBRAHIM R, WANG H. Advances in Biomimetic Nerve Guidance Conduits for Peripheral Nerve Regeneration. Nanomaterials (Basel). 2023;13(18):2528.
[45] WU X, LI H, YIN J, et al. [Experimental study on the construction of telmisartan/collagen/polycaprolactone nerve conduit and its repair effect on rat sciatic nerve defect]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2022;36(3):352-361.
[46] LI Y, KAMEI Y, KAMBE M, et al. Peripheral Nerve Regeneration Using Different Germ Layer-Derived Adult Stem Cells in the Past Decade. Behav Neurol. 2021;2021:5586523.